Occurrence of hemolytic anemia in patients with GBS treated with high-dose IVIg

OBJECTIVE: We describe an underrecognized side effect of high-dose IV immunoglobulin (IVIg), hemolytic anemia. BACKGROUND: There are no established guidelines on treating patients with Guillain-Barré syndrome (GBS) who relapse or do not improve after a standard course of treatment (IVIg or plasma ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Thy P., Biliciler, Suur, Wahed, Amer, Sheikh, Kazim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2014
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268039/
https://www.ncbi.nlm.nih.gov/pubmed/25520957
http://dx.doi.org/10.1212/NXI.0000000000000050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4268039/
https://www.ncbi.nlm.nih.gov/pubmed/25520957
http://dx.doi.org/10.1212/NXI.0000000000000050

Ejemplares similares